Vincristine without a cap? So …
1994; Wiley; Volume: 73; Issue: 10 Linguagem: Inglês
10.1002/1097-0142(19940515)73
ISSN1097-0142
Autores Tópico(s)Cancer Treatment and Pharmacology
ResumoCancerVolume 73, Issue 10 p. 2457-2458 EditorialFree Access Vincristine without a cap? So … Sandra J. Horning M.D., Sandra J. Horning M.D. Department of Medicine, Division of Oncology, Stanford University, Stanford, CaliforniaSearch for more papers by this author Sandra J. Horning M.D., Sandra J. Horning M.D. Department of Medicine, Division of Oncology, Stanford University, Stanford, CaliforniaSearch for more papers by this author First published: 15 May 1994 https://doi.org/10.1002/1097-0142(19940515)73:10 3.0.CO;2-7Citations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E. Full dose vincristine (without 2 mg dose limit) in the treatment of lymphomas. Cancer 1994; 73: 2515– 9. 2 Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295– 1302. 3 Meyer RM, Quirt IC, Skillings JR, Cripps MC, Bramwell VHC, Weinerman BH, et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 1770– 6. 4 Bartlett NB, Rosenberg SA, Hoppe RT, Horning SJ. 12 weeks of chemotherapy and involved field radiotherapy (RT) are highly effective for unfavorable Hodgkin's disease (HD): the Stanford V regimen [abstract]. Blood 1993; 80: 333. 5 Weber DM, Dimopoulos MA, Alexanian R. Increased neurotoxicity with VAD-cyclosporin in multiple myeloma (letter). Lancet 1993; 341: 558– 9. 6 Bertrand Y, Capdeville R, Balduck N, Philippe N. Cyclosporine A used to reverse drug resistance increases vincristine neurotoxicity (letter). Am J Hematol 1992; 40: 158– 9. 7 Jackson DV, Wells HB, Zehan PJ, White DR, Richards F, Cruz JM, et al. Amelioration of vincristine neuropathy by glutamic acid. JAMA 1988; 84: 1016– 22. 8 van Kooten B, van Diemen HAM, Groenhout KM, Huijgens PC, Ossenkoppele GJ, Nauta JJP, et al. A pilot study on the influence of a corticotropin (4–9) analogue on vinca alkaloid-induced neuropathy. Arch Neurol 1992; 49: 1027– 31. 9 van der Hoop RG, Vecht CJ, van der Burg MEL, Elderson A, Boogerd W, Heimans JJ, et al. Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer. New Engl J Med 1990; 322: 89– 94. 10 Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1002– 6. Citing Literature Volume73, Issue1015 May 1994Pages 2457-2458 ReferencesRelatedInformation
Referência(s)